Can Cellares automation move Papillon’s PPL-001 closer to a Friedreich’s ataxia trial?
Cellares will automate PPL-001 manufacturing for Friedreich’s ataxia, but IND-enabling work and human evidence remain ahead.
Pharma & Biotech
Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape?
Larimar’s rolling BLA submission and long-term nomlabofusp data strengthen the case for a potential disease-modifying Friedreich’s ataxia therapy.